



**EFFECTS OF GARLIC POWDER ON GLYCEMIC CONTROL IN THE
PATIENTS OF TYPE-2 DIABETES MELLITUS**

¹Memoona Fareed

¹H.H. SKBZH Muzaffarabad

***²Jan Said**

²Specialist Family Physician, Family Medicine, AHS, SEHA, Abu Dhabi, United Arab Emirates

³Kashaf Munir

³Divisional headquarter and teaching hospital mirpur AJK

⁴Dr Aniba Tabassum

⁴FMO at BHU Dewan Gorra District Sudhnoti

⁵Dr Irslan hussain khan

⁵BHU Deesah Phagwati.

⁶Shafaq Zafar

⁶Associate Professor Department: Pharmacology, Peshawar Medical College, Riphah International University Islamabad

⁷Dr. Muhammad Faisal Nadeem

⁷Assistant Professor, University of Veterinary and Animal Sciences, Lahore

⁸Kashif Lodhi

⁸Department of Agricultural, Food and Environmental Sciences. Università Politénica delle Marche Via Brece Bianche 10, 60131 Ancona (AN) Italy

Corresponding: Jan Said, Email: drjan41@hotmail.com

ABSTRACT

Background: Diabetes Mellitus is one of the most common health hazards in the world, especially in the South Asian region, with 9.2% of the Pakistani population suffering from type-2 diabetes mellitus. This can lead to many complications if glycemic control is not properly monitored. Garlic is one natural product containing sulphur compounds that act as hypoglycemic agents.

Objective: To evaluate the effects of Garlic powder on glycemic index in the patients of type-2diabetes along with allopathic therapy.

Methodology: This RCT includes 80 patients divided into 2 groups. Each group included 40 diagnosed cases of type-2 diabetes. Patients in Group A were taking only oral hypoglycemic drugs, while patients in Group B were receiving formulated capsules of garlic powder along with oral hypoglycemic drugs for six

months. Blood samples were taken at zero level, level-I, and level-II for analysis of fasting and random blood glucose levels and HbA1C.

Results: The outcomes of garlic therapy were observed, and there was significantly ($p < 0.05$) good glyceemic control with garlic therapy as compared with allopathic therapy alone.

Conclusion: The results concluded that there was a marvellous role for natural remedies like garlic powder in conjunction with allopathic therapy in the management of type-2 diabetic patients with a satisfactory glyceemic index.

Key Words: Type-2 Diabetes Mellitus, Garlic Powder, Glyceemic Index.

INTRODUCTION

Diabetes mellitus is one of the leading causes of morbidity at a global level.¹ The global impact of diabetes is increasing day by day. The World Health Organization (W.H.O.) predicts that more than 400 million people will suffer by 2030.² Type-2 diabetes affects 80–90% of the diabetic population, with the remaining 15–20% of the population having type-1 diabetes mellitus.³ Elder age, overweight, lack of physical activity, etc. are the predisposing factors of type-2 diabetes in the diabetic population.⁴

Some research studies have also proved that depression is one of the leading predisposing factors to type-2 diabetes mellitus nowadays.⁵ Allopathic drugs are used for the treatment of type-2 diabetes mellitus all over the world. But before 25 years, when allopathic medicine was not popular or discovered properly, the diabetic population used homoeopathic medicines and natural remedies like olive oil, garlic, ginger, etc.⁶ Because 60 to 70% of the population in Asian countries like Pakistan has a middle to low socioeconomic status and cannot afford allopathic drugs due to their high cost, and some diabetic patients avoid using allopathic medicine due to its side effects, people continue to rely on natural remedies to manage these morbid diseases.⁷

Garlic is one of the old natural herbs cultivated all over the world in 122 countries, which is used as a vegetable as well as a natural medicine.^{8,9} It contains sulphur compounds like allicin and di-allylallycin, which act as antioxidants as well.¹⁰ In the past decades, garlic was used as a drug for the treatment of hypertension, bronchial asthma, colorectal carcinoma, bacterial infections, etc. 11Some research studies have shown that garlic acts as an antihypertensive and anti-diabetic agent.¹¹

METHODOLOGY

This Randomized Control Trial (RCT) was conducted at the University of Sindh and LUMHS with a duration of six months from July 2017 to December 2018. A total of 80 diagnosed cases of Type-2 diabetes have been recruited for this study. All subjects were divided into two groups, A and B, each group containing 40 subjects. Group A received only allopathic therapy (tab. Getformin 2/500mg), while group B received allopathic therapy with a short dose (tab. Glucophage 500mg) along with formulated capsules of garlic powder. Each capsule contained 500mg of garlic powder.

Diagnosed cases of type-2 diabetes mellitus with an age between 40 and 60 years without any diabetic complications were included in this research study, while cases of type-1 diabetes, type-2 diabetes below the age of 40 or above the age of 60 years, pregnant women, diabetic complications, and any history of allergy to garlic were excluded.

For the analysis of parameters under study, blood samples were drawn by venipuncture under sterilised aseptic measurement from all the subjects at three steps during the study research. Fasting blood glucose level (FBS), random blood glucose level (RBS), and HbA1c% were measured at zero (before treatment began), level-I (after three months of treatment), and level-II (after six months of treatment).

FBS and RBS were measured by the glucose oxidase method while HbA1c% was detected by the Microlabfrom Diagnostic & Research Laboratory of LUMHS Jamshoro, Sindh. The data and results were statistically analysed by SPSS version 22 by applying the student *t* test and the chi-square test.

RESULTS


A total of 80 diagnosed cases of type 2 diabetes mellitus were chosen and divided into two groups: group A, which served as the control group, contained 40 cases (26 males and 14 females), and group B, which served as the case study group, also contained 40 cases (28 males and 12 females). The blood samples were taken and analysed before the start of the treatment (zero level), after three months (level-I) of treatment, and after six months of treatment (level-II). Group A patients received only allopathic therapy in the form of a combination of two hypoglycemic drugs, available under the name of Tab. Getformin 2/500mg was given after the meal two times a day, while group B received only one group of hypoglycemic drugs, i.e. metformin, available under the name Tab.Glucophage 500 mg two times a day, along with formulated capsules of garlic powder (500mg) two times a day with a proper diet control chart. The detailed analysis of all parameters like FBS, RBS, and HbA1c% is summarised as follows:

Table no: 01: The Mean values of FBS,RBS & HbA1c% of Control & Case Study Group

| Parameter | Group A (Control Group) | | | Group B (Case Study Group) | | |
|----------------------------------|-------------------------|---------|----------|----------------------------|---------|----------|
| | Level - 0 | Level-I | Level-II | Level-0 | Level-I | Level-II |
| FBS (mg/dl) (70 -110) | 182 | 139 | 101 | 184 | 117 | 82* |
| RBS (mg/dl) (110-160) | 277 | 201 | 174 | 269 | 189 | 147 ** |
| HbA1c% (< 6.5%) | 9.8 | 8.3 | 7.4 | 9.2 | 7.8 | 5.9 ** |


The above table shows the difference in Fasting Blood Glucose, Random Blood Glucose and HBA1C of participants in Level 0, I and II. Statistically significant (* = p value < 0.05) decrease is seen at Level 0 and level II in all three parameters. Highly statistically significant (** = p value = < 0.001) decrease is seen in mean RBS from 277 mg/dl to 147 mg/dl and HBA1C level from 9.8 % to 5.9%.

Graph No: 01: FBS & RBS of Control & Case Study Group



The above graph No. 01 shows the comparison of mean FBS and mean RBS level between study group and control group. From the above data significant difference was observed in study group as compared with control.

Graph No:02: HbA1c% (Glycemic Index) of Control & Case Study Group



The above Graph No. 02 shows the comparison of mean HBA1C level between study group and control group. From the above data significant decrease in mean HBA1C was noted in study group as compared with control.

This RCT research study gave the result that fasting blood glucose levels were significantly ($p < 0.05$) reduced with allopathic therapy along with natural therapy like garlic powder. The same scenario was also observed in random blood sugar and glyceemic control, which more significantly ($p = 0.001$) declined in group B as compared to group A.

DISCUSSION

Garlic has been reported as having anti-diabetic, antibacterial, and anti-dyslipidemic properties.¹² The contents of garlic are different in its different formulated forms, like garlic powder, garlic oil, and garlic extraction.¹³ The results also vary with different forms of garlic. The alliin and allinase enzyme are the primary compounds present in the garlic bulb. Activation of the allinase enzyme during the chopping and crushing process converts alliin to allicin compound powder contains these three compounds.¹⁴ The adenosine compounds are present in raw garlic. Antioxidant compounds like allixin and selenium are present in garlic extract.¹⁵ Garlic oil contains high sulphur compounds like Diallyl, Dimethylallyl etc.¹⁶ According to various studies, allicin is the primary compound that controls diabetes mellitus. Two important bioactive compounds, allyl-2-propenethiosulfinate or diallylthiosulfinate, are derivatives of allicin, which has anti-diabetic effects in a type-1 diabetes rat model study.¹⁷ Allicin also increases the quick release of insulin from beta cells in the pancreas, resulting in a quick response in the reduction of FBS and control of glyceemic control.

Different RCTs were done on the effects of garlic on FBS, RBS, and glyceemic control. Like Sobinen IA et al (2008)¹⁸, they did an RCT for 4 weeks but found no impact on FBS and glyceemic control. Like Ashraf A et al (2011)¹⁹, they did an RCT for 12 weeks but did not get significant results. While our findings are in favour of Ebadi et al. (2007)²⁰, they reported a positive significant relationship between garlic tablets and glyceemic control. They were given garlic 400 mg powder three times a day along with metformin for 12 weeks, and our results also match those of Khedmian et al. (2016)²¹. He studied 50 patients with type-2 diabetes and observed the glyceemic control and lipid profile.

It should be noted that all RCTs were conducted with combination therapy, not monotherapy, and that one placebo study was conducted for a very short period of time, only three weeks, so the results were not statistically significant.

The limitation in this study is that this RCT was also done with a combination of allopathic therapies. In the future, there is a need to research the effects of garlic on glycemic control with monotherapy agents compared with allopathic therapy, and also, there is a need to calculate and give the proper dosage of garlic powder with proper duration of study.

CONCLUSION

This study concluded that garlic has significant effects on glycemic control along with allopathic therapy as compared to allopathic therapy alone in patients with type-2 diabetes mellitus.

CONFLICT OF INTEREST

There is no any conflict of interest.

REFERENCES

1. Li H, Lu W, Wang A, Jiang H, Lyu J. Changing epidemiology of chronic kidney disease as a result of type 2 diabetes mellitus from 1990 to 2017: Estimates from Global Burden of Disease 2017. *Journal of diabetes investigation*. 2021 Mar;12(3):346.
2. Liu J, Ren ZH, Qiang H, Wu J, Shen M, Zhang L, Lyu J. Trends in the incidence of diabetes mellitus: results from the Global Burden of Disease Study 2017 and implications for diabetes mellitus prevention. *BMC public health*. 2020 Dec;20(1):1-2.
3. Morton JJ, Liew D, McDonald SP, Shaw JE, Magliano DJ. The association between age of onset of type 2 diabetes and the long-term risk of end-stage kidney disease: a national registry study. *Diabetes Care*. 2020 Aug 1;43(8):1788-95.
4. Sazlina SG, Lee PY, Chan YM, A. Hamid MS, Tan NC. The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in Malaysia. *PloS one*. 2020 May 20;15(5):e0233299.
5. de Alba IG, Gimeno-Miguel A, Poblador-Plou B, Gimeno-Feliu LA, Ioakeim-Skoufa I, Rojo-Martínez G, Forjaz MJ, Prados-Torres A. Association between mental health comorbidity and health outcomes in type 2 diabetes mellitus patients. *Scientific reports*. 2020 Nov 11;10(1):1-9.
6. Rathi J, Kumar S, Kumari B, Khansili A, Narwal S, Purohit D, Manchanda D, Makhija M, Saini S, Pandey P. Role of Herbal Medicines in the Treatment of Diabetes Mellitus: An Updated Review. *Annals of the Romanian Society for Cell Biology*. 2021 Jun 23;25(6):13190-9.
7. Narayan KV, Kanaya AM. Why are South Asians prone to type 2 diabetes? A hypothesis based on underexplored pathways. *Diabetologia*. 2020 Jun;63(6):1103-9.
8. Rouf R, Uddin SJ, Sarker DK, Islam MT, Ali ES, Shilpi JA, Nahar L, Tiralongo E, Sarker SD. Anti-viral potential of garlic (*Allium sativum*) and its organosulfur compounds: a systematic update of pre-clinical and clinical data. *Trends in food science & technology*. 2020 Aug 19.
9. Saryıldız T. Effects of leonardite and mineral fertilizer applications on plant growth and soil quality of garlic (*Allium sativum* L.). *Turkish Journal of Agriculture-Food Science and Technology*. 2020 Aug 30;8(8):1763-72.
10. El-Saber Batiha G, MagdyBeshbishy A, G Wasef L, Elewa YH, A Al-Sagan A, El-Hack A, Mohamed E, Taha AE, M Abd-Elhakim Y, Prasad Devkota H. Chemical constituents and pharmacological activities of garlic (*Allium sativum* L.): A review. *Nutrients*. 2020 Mar;12(3):872.
11. Nasir A, Fatma G, Neshat N, Ahmad MA. Pharmacological and therapeutic attributes of garlic (*Allium sativum* Linn.) with special reference to Unani medicine—A review. *J. Med. Plants Stud*. 2020;8:6-9.
12. Tavares L, Santos L, Noreña CP. Bioactive compounds of garlic: A comprehensive review of encapsulation technologies, characterization of the encapsulated garlic compounds and their industrial applicability. *Trends in Food Science & Technology*. 2021 May 27.

13. Janská P, Knejzlík Z, Perumal AS, Jurok R, Tokárová V, Nicolau DV, Štěpánek F, Kašpar O. Effect of physicochemical parameters on the stability and activity of garlic alliinase and its use for in-situ allicin synthesis. *Plos one*. 2021 Mar 19;16(3):e0248878.
14. Tazikeh T, AbedianKenari A, Esmaeili M. Effects of fish meal replacement by meat and bone meal supplemented with garlic (*Allium sativum*) powder on biological indices, feeding, muscle composition, fatty acid and amino acid profiles of whiteleg shrimp (*Litopenaeus vannamei*). *Aquaculture Research*. 2020 Feb;51(2):674-86.
15. Attia KM, Assar MH, Farouk ZM, Basuney HA. Possible Protective Effects of Black Seed (*Nigella Sativa*) or Garlic (*Allium Sativum*) Against Lead-Induced Toxicity in growing rabbits. *Alexandria Journal for Veterinary Sciences*. 2020 Apr 1;64(2).
16. Yousef EA, Elsadek MA. A Comparative study of morphological and volatile oil composition characteristics in diploid and tetraploid garlic plants. *Egyptian Journal of Horticulture*. 2020 Apr 1;47(1):1-4.
17. Faisal AN. The Role of Allicin in Regulating Insulin and Glycemic Level in White Mice with Induced Insulin Resistance. *Annals of the Romanian Society for Cell Biology*. 2021 Apr 25:10921-8.
18. Sobenin IA, Nedosugova LV, Filatova LV, et al. Metabolic effects of time-released garlic powder tablets in type 2 diabetes mellitus: the results of double-blinded placebo controlled study. *Acta Diabetol*. 2008;45(1):1–6.
19. Ashraf R, Khan RA, Ashraf I. Garlic (*Allium sativum*) supplementation with standard antidiabetic agent provides better diabetic control in type 2 diabetes patients. *Pak J Pharm Sci*. 2011;24(4):565–570.
20. Ebadi A, RahimiLenji A, Taghadosi M, Khorshidi A, Akbari H. The effect of garlic pills on blood glucose in type 2 diabetic patients. *Feyz Scientific-Research Quarterly*, 2007; 11 (1): 20-25.
21. Khademian R, Mozafari H, Esteghamati A, Pasha Meisami A. Study of the effect of taking blood glucose tablets and lipid profile in patients with type 2 diabetes an unannounced randomized clinical trial. *Journal of Shaheed Sadoughi University of Medical Sciences Yazd*, 2016; 22(7): 621-630.